Global Regulators Join Hands To Boost RWE Use In Decision-Making
Executive Summary
Existing challenges to using real-world evidence such as heterogeneous data sources around the world and the various governance models for data sharing and access will need to be addressed.
You may also be interested in...
ICH Takes First Step In Bid To Align RWE Use Globally
Supporting the creation of a regulatory system that integrates real-world evidence in submissions for medicines approval and decision-making in a more harmonized way can support timely decisions on the development of innovative treatments and help address unmet medical needs, according to the International Council for Harmonisation.
Collaboration Makes The (Real) World Go Round: Global Efforts Strive To Anchor RWE With Real-World Data Standards And Practices
Can the decentralized global healthcare ecosystem to turn real-world evidence from a buzzword to a useful approach to fit-for-purpose evidence generation?
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.